FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206960604> ?p ?o ?g. }

• W4206960604 endingPage "172" @default.
• W4206960604 startingPage "157" @default.
• W4206960604 abstract "To compare the efficacy and safety of brolucizumab with aflibercept in patients with diabetic macular edema (DME).Double-masked, 100-week, multicenter, active-controlled, randomized trials.Subjects were randomized 1:1:1 to brolucizumab 3 mg/6 mg or aflibercept 2 mg in KESTREL (n = 566) or 1:1 to brolucizumab 6 mg or aflibercept 2 mg in KITE (n = 360). Brolucizumab groups received 5 loading doses every 6 weeks (q6w) followed by 12-week (q12w) dosing, with optional adjustment to every 8 weeks (q8w) if disease activity was identified at predefined assessment visits; aflibercept groups received 5 doses every 4 weeks (q4w) followed by fixed q8w dosing. The primary endpoint was best-corrected visual acuity (BCVA) change from baseline at Week 52; secondary endpoints included the proportion of subjects maintained on q12w dosing, change in Diabetic Retinopathy Severity Scale score, and anatomical and safety outcomes.At Week 52, brolucizumab 6 mg was noninferior (NI margin 4 letters) to aflibercept in mean change in BCVA from baseline (KESTREL: +9.2 letters vs +10.5 letters; KITE: +10.6 letters vs +9.4 letters; P < .001), more subjects achieved central subfield thickness (CSFT) <280 µm, and fewer had persisting subretinal and/or intraretinal fluid vs aflibercept, with more than half of brolucizumab 6 mg subjects maintained on q12w dosing after loading. In KITE, brolucizumab 6 mg showed superior improvements in change of CSFT from baseline over Week 40 to Week 52 vs aflibercept (P = .001). The incidence of ocular serious adverse events was 3.7% (brolucizumab 3 mg), 1.1% (brolucizumab 6 mg), and 2.1% (aflibercept) in KESTREL; and 2.2% (brolucizumab 6 mg) and 1.7% (aflibercept) in KITE.Brolucizumab 6 mg showed robust visual gains and anatomical improvements with an overall favorable benefit/risk profile in patients with DME." @default.
• W4206960604 created "2022-01-26" @default.
• W4206960604 creator A5010334968 @default.
• W4206960604 creator A5015335649 @default.
• W4206960604 creator A5017440565 @default.
• W4206960604 creator A5018800623 @default.
• W4206960604 creator A5024313268 @default.
• W4206960604 creator A5028719257 @default.
• W4206960604 creator A5030449236 @default.
• W4206960604 creator A5030489879 @default.
• W4206960604 creator A5035546311 @default.
• W4206960604 creator A5037985769 @default.
• W4206960604 creator A5039325608 @default.
• W4206960604 creator A5040712843 @default.
• W4206960604 creator A5056909319 @default.
• W4206960604 creator A5072127135 @default.
• W4206960604 creator A5073769815 @default.
• W4206960604 creator A5075928522 @default.
• W4206960604 creator A5079233616 @default.
• W4206960604 creator A5083564913 @default.
• W4206960604 creator A5086662698 @default.
• W4206960604 date "2022-06-01" @default.
• W4206960604 modified "2023-10-16" @default.
• W4206960604 title "KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema" @default.
• W4206960604 cites W1492470838 @default.
• W4206960604 cites W1782108791 @default.
• W4206960604 cites W2087598211 @default.
• W4206960604 cites W2102463203 @default.
• W4206960604 cites W2161279821 @default.
• W4206960604 cites W2226585534 @default.
• W4206960604 cites W2289200040 @default.
• W4206960604 cites W2523833186 @default.
• W4206960604 cites W2591137745 @default.
• W4206960604 cites W2605619962 @default.
• W4206960604 cites W2616361514 @default.
• W4206960604 cites W2766315223 @default.
• W4206960604 cites W2767373868 @default.
• W4206960604 cites W2791723584 @default.
• W4206960604 cites W2799394289 @default.
• W4206960604 cites W2894838826 @default.
• W4206960604 cites W2936430874 @default.
• W4206960604 cites W2958970461 @default.
• W4206960604 cites W2985982097 @default.
• W4206960604 cites W2999438498 @default.
• W4206960604 cites W3024108708 @default.
• W4206960604 cites W3030682574 @default.
• W4206960604 cites W3035836792 @default.
• W4206960604 cites W3158522809 @default.
• W4206960604 cites W922383587 @default.
• W4206960604 doi "https://doi.org/10.1016/j.ajo.2022.01.004" @default.
• W4206960604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35038415" @default.
• W4206960604 hasPublicationYear "2022" @default.
• W4206960604 type Work @default.
• W4206960604 citedByCount "53" @default.
• W4206960604 countsByYear W42069606042022 @default.
• W4206960604 countsByYear W42069606042023 @default.
• W4206960604 crossrefType "journal-article" @default.
• W4206960604 hasAuthorship W4206960604A5010334968 @default.
• W4206960604 hasAuthorship W4206960604A5015335649 @default.
• W4206960604 hasAuthorship W4206960604A5017440565 @default.
• W4206960604 hasAuthorship W4206960604A5018800623 @default.
• W4206960604 hasAuthorship W4206960604A5024313268 @default.
• W4206960604 hasAuthorship W4206960604A5028719257 @default.
• W4206960604 hasAuthorship W4206960604A5030449236 @default.
• W4206960604 hasAuthorship W4206960604A5030489879 @default.
• W4206960604 hasAuthorship W4206960604A5035546311 @default.
• W4206960604 hasAuthorship W4206960604A5037985769 @default.
• W4206960604 hasAuthorship W4206960604A5039325608 @default.
• W4206960604 hasAuthorship W4206960604A5040712843 @default.
• W4206960604 hasAuthorship W4206960604A5056909319 @default.
• W4206960604 hasAuthorship W4206960604A5072127135 @default.
• W4206960604 hasAuthorship W4206960604A5073769815 @default.
• W4206960604 hasAuthorship W4206960604A5075928522 @default.
• W4206960604 hasAuthorship W4206960604A5079233616 @default.
• W4206960604 hasAuthorship W4206960604A5083564913 @default.
• W4206960604 hasAuthorship W4206960604A5086662698 @default.
• W4206960604 hasBestOaLocation W42069606041 @default.
• W4206960604 hasConcept C118487528 @default.
• W4206960604 hasConcept C126322002 @default.
• W4206960604 hasConcept C134018914 @default.
• W4206960604 hasConcept C141071460 @default.
• W4206960604 hasConcept C168563851 @default.
• W4206960604 hasConcept C197934379 @default.
• W4206960604 hasConcept C203092338 @default.
• W4206960604 hasConcept C2776694085 @default.
• W4206960604 hasConcept C2777288759 @default.
• W4206960604 hasConcept C2777802072 @default.
• W4206960604 hasConcept C2778257484 @default.
• W4206960604 hasConcept C2778749236 @default.
• W4206960604 hasConcept C2779829184 @default.
• W4206960604 hasConcept C2780347916 @default.
• W4206960604 hasConcept C555293320 @default.
• W4206960604 hasConcept C71924100 @default.
• W4206960604 hasConceptScore W4206960604C118487528 @default.
• W4206960604 hasConceptScore W4206960604C126322002 @default.
• W4206960604 hasConceptScore W4206960604C134018914 @default.
• W4206960604 hasConceptScore W4206960604C141071460 @default.
• W4206960604 hasConceptScore W4206960604C168563851 @default.

• next